This study will examine the development of stem cells (very immature cells produced by the
bone marrow) and their potential to change into cells of other organ types. These cells will
be studied for their potential use in creating replacement tissue for diseases ranging from
diabetes to Parkinson s.
Healthy volunteers 18 years of age or older may be eligible for this study. Candidates will
be screened with a medical history, physical examination, and blood tests.
Participants will undergo a process called 'stem cell mobilization and apheresis' to collect
bone marrow stem cells. For five days before the collection they will receive injections of a
hormone called G-CSF, which stimulates release of stem cells from the bone marrow into the
bloodstream. On the fifth day of the injections, stem cells will be collected through
apheresis. For this procedure, blood is collected through a catheter (plastic tube) placed in
an arm vein and directed into a cell separator machine. There, the white cells and stem cells
are separated from the other blood components through a spinning process and collected in a
bag inside the machine. The rest of the blood is returned to the donor through a catheter in
the other arm.
The renewal of various tissues and organs at steady state or following damage relies upon a
small population of locally residing tissue specific "stem cells" Stem cells from adult bone
marrow represent an ideal stem cell source based on their ease of collection. In order to
begin to explore the potential of adult bone marrow for the correction of genetic diseases
that affect the blood such as sickle cell disease, we propose in vitro and in vivo mouse
studies to examine the regulation of normal differentiation of hematopoietic stem cells
collected from adult volunteers. In order to obtain adult hematopoietic stem cells in large
numbers for in vitro and in vivo studies, volunteers will undergo mobilization with G-CSF for
5 consecutive days followed by large volume apheresis on the 5th day of G-CSF injection. The
harvested product will be immunomagnetically purified for the primitive progenitor population
and viably cryopreserved in multiple aliquots.
- INCLUSION CRITERIA:
Age 18 or greater.
Normal renal function: creatinine less than1.5 mg/dL, proteinuria less than1+.
Normal liver function: bilirubin less than 2.5 mg/dL, ALT less than 2.5 times the upper
limit of normal, all other transminases less than 2.5 times the upper limit of normal.
Normal blood counts: WBC 3,000-10,000/mm3, granulocytes greater than 1,500/mm3, platelets
greater than 150,000/mm3, hemoglobin greater than 12.5g/dL, MCV within normal limits.
Female volunteers of childbearing age should have a negative serum pregnancy test within
one week of beginning G-CSF administration.
Meets NIH Department of Transfusion Medicine (DTM) eligibility criteria for blood component
donation for in vitro research use (negative serologic tests for syphilis, hepatitis B and
C, HIV, and HTLV-1).
Ability to give informed consent to participate in the protocol.
Any underlying hematologic disorder including sickle cell disease.
Active viral, bacterial, fungal, or parasitic infection.
History of autoimmune disease, such as rheumatoid arthritis or systemic lupus
History of cancer excluding squamous carcinoma of the skin and cervical carcinoma in situ.
History of cardiovascular disease or related symptoms such as chest pain or shortness of
Any positive serum screening test as listed below.
Allergy to G-CSF or bacterial E. coli products.
John F Tisdale, M.D.
National Heart, Lung, and Blood Institute (NHLBI)
John F Tisdale, M.D.
Phone: (301) 402-6497